Home>News>Company News
R&G as The Only China CRO Presence at the 26th TCT Meeting

The 26thTranscatheter Cardiovascular Therapeutics(TCT) is held on September 13th to 17th in Washington D.C, U.S.A. For over 25 years, TCT has been the center of cutting-edge technology communication, experience sharing and education among the world’s intervention physicians. And TCT is currently the world’s most influential meeting specialized in interventional cardiovascular medicine.

R&G is the only one CRO from China attending this event. During the meeting, R&G BD delegations introduced the new released device regulations from CFDA, the strategy and pathway to enter China market, and R&G’s capability and experience of medical device registration and clinical trial operation to all the world’s top and small-middle scale interventional cardiovascular companies and thousands of intervention cardiologists from the world. There is great potential for cooperation in the near future.

© 2019 R&G PharmaStudies Co., Ltd. All Rights Reserved  京ICP备11047511-1